Actually GNBT could get up-listed to NASDAQ before the NGIO IPO (quite soon) if the public will realize/accept the NGIO 3rd party evaluation. My calculations on Post# 25202 puts GNBT at a $4.37/share value if the $500,000,000 is included. It shouldn’t matter if NGIO is publicly traded or not. An asset is an asset, and if GNBT owns an asset worth $500 million, that needs to be included. This amount should appear on the next 10-Q balance sheet. Then let the naysayers try to fog it off.
(1)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links